The Influence of Changes in Tumor Hypoxia on Dose-Painting Treatment Plans Based on 18F-FMISO Positron Emission Tomography

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 4, 2008, Pages 1219-1228

  Lin, Zhixiong ^a   Mechalakos, James ^b   Nehmeh, Sadek ^b   Schoder, Heiko ^b   Lee, Nancy ^b   Humm, John ^b   Ling, C Clifton ^b,c  

^a CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c VARIAN MEDICAL SYSTEMS   (United States)

Author keywords

18F FMISO PET; Dose painting; Tumor hypoxia

Indexed keywords

MEDICAL IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY;

DOSE PAINTING; HYPOXIC VOLUMES; TUMOR HYPOXIA;

TUMORS;

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; TREATMENT PLANNING; TUMOR VOLUME;

CELL HYPOXIA; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MISONIDAZOLE; POSITRON-EMISSION TOMOGRAPHY; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 39749194493     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.09.050     Document Type: Article

References (31)

1. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 (1998) 1798-1804
2. Budach V., Stuschke M., Budach W., et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23 (2005) 1125-1135
3. Chao K.S.C., Deasy J.O., Markman J., et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: Initial results. Int J Radiat Oncol Biol Phys 49 (2001) 907-916
4. Lee N., Xia P., Quivey J.M., et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys 53 (2002) 12-22
5. Lee N., Xia P., Fischbein N.J., et al. Intensity-modulated radiation therapy for head-and-neck cancer: The UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 57 (2003) 49-60
6. Chao K.S.C., Ozyigit G., Tran B.N., et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 55 (2003) 312-321
7. Thomlinson R., and Gray L. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9 (1955) 539-549
8. Hockel M., Knoop C., Schlenger K., et al. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv Exp Med Biol 345 (1994) 445-450
9. Hockel M., Schlenger K., Aral B., et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
10. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
11. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
12. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. [see comments]. Nature 379 (1996) 88-91
13. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
14. Rofstad E.K. Microenvironment-induced cancer metastasis. Int J Radiat Biol 76 (2000) 589-605
15. De Jaeger K., Kavanagh M.C., and Hill R.P. Relationship of hypoxia to metastatic ability in rodent tumours. Br J Cancer 84 (2001) 1280-1285
16. Brown J.M. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine. Br J Cancer 77 Suppl. 4 (1998) 12-14
17. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23 (2005) 79-87
18. Kaanders J.H.A.M., Pop L.A.M., Marres H.A.M., et al. ARCON: Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 52 (2002) 769-778
19. Ling C.C., Humm J., Larson S., et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47 (2000) 551-560
20. Chao K.S., Bosch W.R., Mutic S., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 1171-1182
21. Gronroos T., Eskola O., Lehtio K., et al. Pharmacokinetics of [18F]FETNIM: A potential marker for PET. J Nucl Med 42 (2001) 1397-1404
22. Dolbier Jr. W.R., Li A.R., Koch C.J., et al. [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 54 (2001) 73-80
23. Dehdashti F., Mintun M., Lewis J., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30 (2003) 844-850
24. Lee N.Y., Mechalakos J.G., Nehmeh S., et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study. Int J Radiat Oncol Biol Phys 70 (2008) 2-13
25. Nehmeh S.A., Schoder H., Lee N.Y., et al. Reproducibility of the intra-tumoral distribution of 18F-flouromisonidazole (18F-MISO) in head and neck cancer. Int J Radiat Oncol Biol Phys 70 (2008) 235-242
26. Rasey J.S., Koh W.J., Evans M.L., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36 (1996) 417-428
27. Rajendran J.G., Schwartz D.L., O'Sullivan J., et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12 (2006) 5435-5441
28. Niemierko A. Reporting and analyzing dose distributions: A concept of equivalent uniform dose. Med Phys 24 (1997) 103-110
29. Popple R.A., Ove R., and Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys 54 (2002) 921-927
30. Chaplin D.J., Olive P.L., and Durand R.E. Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res 47 (1987) 597-601
31. Dewhirst M.W., Braun R.D., and Lanzen J.L. Temporal changes in pO2 of R3230Ac tumors in fischer-344 rats. Int J Radiat Oncol Biol Phys 42 (1998) 723-726